These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 1375012)

  • 21. [Sweet syndrome following therapeutic use of granulocyte colony stimulating factor].
    Veres K; Haraszti A; Nemes Z; Zeher M
    Orv Hetil; 1999 May; 140(19):1059-61. PubMed ID: 10339998
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sweet's syndrome associated with granulocyte colony-stimulating factor.
    Hasegawa M; Sato S; Nakada M; Nitta H; Shirasaki H; Kasahara K; Takehara K
    Eur J Dermatol; 1998; 8(7):503-5. PubMed ID: 9854164
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Role of G-CSF for breast cancer chemotherapy].
    Suzuki Y; Saito Y; Tokuda Y
    Nihon Rinsho; 2007 Jun; 65 Suppl 6():572-4. PubMed ID: 17679213
    [No Abstract]   [Full Text] [Related]  

  • 24. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
    Hershman D; Neugut AI; Jacobson JS; Wang J; Tsai WY; McBride R; Bennett CL; Grann VR
    J Natl Cancer Inst; 2007 Feb; 99(3):196-205. PubMed ID: 17284714
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative effects of three cytokine regimens after high-dose cyclophosphamide: granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor (GM-CSF), and sequential interleukin-3 and GM-CSF.
    Ballestrero A; Ferrando F; Garuti A; Basta P; Gonella R; Stura P; Mela GS; Sessarego M; Gobbi M; Patrone F
    J Clin Oncol; 1999 Apr; 17(4):1296. PubMed ID: 10561192
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Re: Adverse effect on bone marrow protection of prechemotherapy granulocyte colony-stimulating factor support.
    Ribas A; Albanell J; Bellmunt J; Solé-Calvo LA
    J Natl Cancer Inst; 1997 Mar; 89(5):395-6. PubMed ID: 9060963
    [No Abstract]   [Full Text] [Related]  

  • 27. Granulocyte-colony stimulating factor fails to prevent leucopenia caused by CEMP in elderly patients with aggressive lymphoma.
    Nel JS; Falkson CI
    S Afr Med J; 1996 Dec; 86(12):1564. PubMed ID: 8998237
    [No Abstract]   [Full Text] [Related]  

  • 28. Sweet's syndrome secondary to granulocyte colony-stimulating factor.
    Prevost-Blank PL; Shwayder TA
    J Am Acad Dermatol; 1996 Dec; 35(6):995-7. PubMed ID: 8959967
    [No Abstract]   [Full Text] [Related]  

  • 29. EPONYM. Sweet syndrome.
    Kim MJ; Choe YH
    Eur J Pediatr; 2010 Dec; 169(12):1439-44. PubMed ID: 20445990
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Clinical study of recombinant human granulocyte colony-stimulating factor (RHG-CSF) on leucopenia induced by chemotherapy with CE regimen on lung cancer patients].
    Shi YK; Feng FY; Sun Y
    Zhonghua Nei Ke Za Zhi; 1994 Nov; 33(11):739-42. PubMed ID: 7541325
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The increase of the rate of hemopoietic recovery and clinical benefit of the erythropoietin (EPO) and granulocyte colony-stimulating factor (G-CSF) with peripheral blood progenitor cells (PBPC) after intensive cyclic chemotherapy in high-risk breast cancer patients.
    Filip S; Vanásek J; Bláha M; Mericka P; Vávrová J; Podzimek K
    Neoplasma; 1999; 46(3):166-72. PubMed ID: 10613592
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Life-threatening complications from doxorubicin-docetaxel chemotherapy for breast cancer.
    Martin M; Vogel C; Crown J; Mackey J
    JAMA; 2005 Nov; 294(17):2166; author reply 2166-7. PubMed ID: 16264153
    [No Abstract]   [Full Text] [Related]  

  • 33. Favorable outcome of severe, extensive, granulocyte colony-stimulating factor-induced, corticosteroid-resistant Sweet's syndrome treated with high-dose intravenous immunoglobulin.
    Calixto R; Menezes Y; Ostronoff M; Sucupira A; Botelho LF; Florencio R; Martins M; Souto Maior AP
    J Clin Oncol; 2014 Feb; 32(5):e1-2. PubMed ID: 24395855
    [No Abstract]   [Full Text] [Related]  

  • 34. Granulocyte colony-stimulating factor: key (f)actor or innocent bystander in the development of secondary myeloid malignancy?
    Touw IP; Bontenbal M
    J Natl Cancer Inst; 2007 Feb; 99(3):183-6. PubMed ID: 17284707
    [No Abstract]   [Full Text] [Related]  

  • 35. [Pancytopenia and macular rash in a woman with a history of breast cancer].
    Jacobi D; Vidal C; Gironet N; Machet MC; Machet L
    Rev Med Interne; 2003 Jun; 24(6):399-400. PubMed ID: 12814830
    [No Abstract]   [Full Text] [Related]  

  • 36. Adjuvant docetaxel for node-positive breast cancer.
    Noronha V
    N Engl J Med; 2005 Sep; 353(9):954-5; author reply 954-5. PubMed ID: 16136712
    [No Abstract]   [Full Text] [Related]  

  • 37. Are dose-dense and triplet chemotherapy regimens optimal adjuvant therapy in the majority of women with node-positive early breast cancer?
    Moylan EJ; Connell LC; O'Reilly S
    J Clin Oncol; 2014 Feb; 32(6):605-6. PubMed ID: 24419118
    [No Abstract]   [Full Text] [Related]  

  • 38. An unusual cause of a marked leukocytosis and an abnormal blood film.
    Hargreaves T; Varey M; Kataria U; Renton B
    Br J Hosp Med (Lond); 2015 Mar; 76(3):174-5. PubMed ID: 25761812
    [No Abstract]   [Full Text] [Related]  

  • 39. Prolonged neutropenia after dose-dense chemotherapy with pegfilgrastim.
    Ishiguro H; Kitano T; Yoshibayashi H; Toi M; Ueno T; Yasuda H; Yanagihara K; Garbo CL; Fukushima M
    Ann Oncol; 2008 May; 19(5):1019; author reply 1019-20. PubMed ID: 18325914
    [No Abstract]   [Full Text] [Related]  

  • 40. Peripheral progenitor cells (PBPC) in supportive care after high-dose chemotherapy in breast cancer.
    Filip S; Bláha M; Petera J; Vavrová J; Knízek J
    Neoplasma; 2001; 48(1):39-47. PubMed ID: 11327536
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.